David Wholley, M.Phil.
David Wholley currently serves as the Interim President and Executive Director and manages the Research Partnerships Division of the Foundation, which is responsible for major research collaborations including the Accelerating Medicines Partnership® Program (AMP®), the Biomarkers Consortium, the LungMAP precision medicine trial in lung cancer, and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Mr. Wholley has also served as Director of the Genetic Association Information Network (GAIN), a public-private partnership dedicated to helping discover the genetic basis of common disease, and led the development of a major public-private partnership in drug safety with the biopharmaceutical industry and FDA. Prior to joining the Foundation in 2006, Mr. Wholley’s career spanned nearly 25 years in healthcare technology business management, including extensive experience in product development, sales, marketing, corporate strategy and partnership and project development. Mr. Wholley has held senior management roles in several venture-funded technology startup companies, including head of Global Marketing and Development for First Genetic Trust, Inc., which developed software for large-scale collaborative genetic research and personalized medicine. During a 16-year career at IBM, he co-led the corporate strategy team that guided IBM’s formation of its Life Sciences industry organization. Mr. Wholley holds an M.Phil from Rutgers University and a Certificate in Business Administration from the Stern School of Business at New York University.
Phone: (301) 443-1811
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services